Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis
From the perspective of the Chinese population, finotonlimab-chemotherapy is the most cost-effective first-line treatment for R/M HNSCC, followed by cetuximab-chemotherapy. Pembrolizumab, whether as monotherapy or in combination, does not offer economic benefits.
Authors
- Gui‐Lin Song (ORCID: https://orcid.org/0000-0001-6683-0777)
- Yong Pan (ORCID: https://orcid.org/0000-0001-9033-719X)
- Xia Qin (ORCID: https://orcid.org/0000-0001-9689-1730)
- Liu Y (ORCID: https://orcid.org/0000-0002-4548-8324)
- Fen Liu (ORCID: https://orcid.org/0000-0001-9214-0016)
- Haonan Li (ORCID: https://orcid.org/0000-0003-1954-641X)
Institutions
- Central South University (CN)
- Yantai University (CN)
- Guangdong Pharmaceutical University (CN)
- Peking University (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3389/fphar.2025.1644426
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 0.00